Marta Llauradó Fernández

University of British Columbia — Canada

Medicine · Health Sciences

11h-index630citations47works3.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ovarian cancer diagnosis and treatment(39), Cancer Mechanisms and Therapy(17), Chromatin Remodeling and Cancer(8), Endometrial and Cervical Cancer Treatments(5), Cancer Genomics and Diagnostics(4)

Publications46 total

Differential Preclinical Efficacy of Combined CDK4/6 and MEK Inhibition in Low-Grade Serous Ovarian Carcinoma Based on KRAS/NF1 Mutational Status
International Journal of Molecular Sciences·2026Open Access
Establishment and characterization of preclinical models of human gynecologic tract carcinosarcomas demonstrates targetable FGFR1 alterations
Translational Oncology·2025Open Access
Establishment and characterization of preclinical models of human gynecologic tract carcinosarcomas demonstrates targetable FGFR1 alterations
SSRN Electronic Journal·2025Open Access
FOLR1 as a therapeutic target in platinum-resistant ovarian carcinoma: unique expression patterns across ovarian carcinoma histotypes and molecular subtypes of low-grade serous carcinoma
Journal of Gynecologic Oncology·2025· 9 citedOpen Access
Preclinical 3D model screening reveals digoxin as an effective therapy for a rare and aggressive type of endometrial cancer
Gynecologic Oncology·2024· 4 citedOpen Access
Molecular Surrogate Subtypes of Ovarian and Peritoneal Low-grade Serous Carcinoma
International Journal of Gynecological Pathology·2024· 6 cited
High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma
Gynecologic Oncology·2024· 9 citedOpen Access
Abstract B054: Defective STING signaling in low-grade serous ovarian cancer: an opportunity for oncolytic viruses therapy
Cancer Research·2024
The spectrum of MAPK-ERK pathway genomic alterations in gynecologic malignancies: Opportunities for novel therapeutic approaches
Gynecologic Oncology·2023· 14 cited
Establishment and validation of preclinical models of SMARCA4-inactivated and ARID1A/ARID1B co-inactivated dedifferentiated endometrial carcinoma
Gynecologic Oncology·2023· 5 cited
Abstract 6417: Deciphering aberrant STING pathway and exploring oncolytic viruses therapy in low grade serous ovarian carcinoma
Cancer Research·2023
Supplementary Data from NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition
2023Open Access
Supplementary Data from NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition
2023Open Access
Supplementary Data from NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition
2023Open Access
Supplementary Figure from NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition
2023Open Access
Data from NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition
2023Open Access
Supplementary Figure from NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition
2023Open Access
Supplementary Data from NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition
2023Open Access
Supplementary Data from NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition
2023Open Access
Data from NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Mark Carey(41), Amy Dawson(31), Joshua Hoenisch(28), Gabriel E. DiMattia(25), Nelson K.Y. Wong(25), Cheng‐Han Lee(16), Madison Bittner(15), Martin Köbel(14), Hannah Kim(14), Stanislav Volik(13), Colin C. Collins(12), Yen‐Yi Lin(11), E. Marielle Hijmans(11), Annemiek M.C. Gennissen(11), Shang Li(11), G. Bea A. Wisman(11), Aleksandra Hamilton(11), Christianne Lok(11), Cor Lieftink(11), Roderick L. Beijersbergen(11)